ProMIS Neurosciences (PMN) Appoints Dr. Slanix Paul Alex to Board

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/24/2026

1. DECK
2. RNG
3. WDC
4. BYD
5. WCN
6. SPOT
7. BMY
8. SPY
9. FIX
10. TSCO

Go back to ProMIS Neurosciences (PMN) Appoints Dr. Slanix Paul Alex to Board

ProMIS Neurosciences Strengthens Board with Appointment of Slanix Paul Alex, Pharm.D., President and Portfolio Manager, Public Equity of Ally Bridge Group

October 22, 2025 7:30 AM EDT

Appointment reinforces ProMIS Neurosciences strategic vision and deepens investor engagement as the Company advances its differentiated Alzheimers program, PMN310

Cambridge, Massachusetts, Oct. 22, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing next-generation therapies for Alzheimers disease (AD) and other neurodegenerative disorders, today announced that Slanix Paul Alex, Pharm.D., President and Portfolio Manager for Ally Bridge Groups Public Equity strategy, has joined the Companys Board of Directors. Dr. Alex has a highly distinguished Wall Street career spanning multiple leadership positions at public markets-focused healthcare... More